Research ExplorerPublicationsCardiovascular Mortality in Patients With Metastatic Prostat...

Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study

Standard

Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. / Gandaglia, Giorgio; Sun, Maxine; Popa, Ioana; Schiffmann, Jonas; Trudeau, Vincent; Shariat, Shahrokh F; Trinh, Quoc-Dien; Graefen, Markus; Widmer, Hugues; Saad, Fred; Briganti, Alberto; Montorsi, Francesco; Karakiewicz, Pierre I.

In: CLIN GENITOURIN CANC, Vol. 13, No. 3, 01.06.2015, p. e123-130.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Gandaglia, G, Sun, M, Popa, I, Schiffmann, J, Trudeau, V, Shariat, SF, Trinh, Q-D, Graefen, M, Widmer, H, Saad, F, Briganti, A, Montorsi, F & Karakiewicz, PI 2015, 'Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study', CLIN GENITOURIN CANC, vol. 13, no. 3, pp. e123-130. https://doi.org/10.1016/j.clgc.2014.12.003

APA

Gandaglia, G., Sun, M., Popa, I., Schiffmann, J., Trudeau, V., Shariat, S. F., Trinh, Q-D., Graefen, M., Widmer, H., Saad, F., Briganti, A., Montorsi, F., & Karakiewicz, P. I. (2015). Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. CLIN GENITOURIN CANC, 13(3), e123-130. https://doi.org/10.1016/j.clgc.2014.12.003

Vancouver

Gandaglia G, Sun M, Popa I, Schiffmann J, Trudeau V, Shariat SF et al. Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. CLIN GENITOURIN CANC. 2015 Jun 1;13(3):e123-130. https://doi.org/10.1016/j.clgc.2014.12.003

Bibtex

@article{afdbbb8cd5bb4352ac7eaf57de5ad678,
title = "Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study",
abstract = "INTRODUCTION: The aim of our study was to reexamine the prevalence of baseline cardiovascular (CV) morbidity and the rates of CV mortality in a contemporary cohort of patients with prostate cancer (PCa) exposed to androgen deprivation therapy (ADT).MATERIALS AND METHODS: Records of patients aged 65 years and older with metastatic PCa who received ADT were abstracted from the Surveillance, Epidemiology, and End Results-Medicare database between 1991 and 2009. The primary end points comprised 5-year CV mortality rates. Survival rates were stratified according to age and Charlson comorbidity index (CCI). Competing-risks Poisson regression methodologies were performed.RESULTS: Overall, 9596 patients with metastatic PCa treated with ADT were identified. At baseline, 3049 patients (31.8%) had preexisting CV disease. The 5-year CV mortality rates were 9.8% and 14.8% in the overall population and in patients with preexisting CV disease, respectively. The 5-year CV mortality rates increased with advanced age and higher CCI score. In multivariate competing-risks regression analyses, age, year of diagnosis, CV comorbidities, CCI, and marital status represented independent predictors of CV mortality, after accounting for the risk of dying from other causes (all P ≤ .04). Of those, preexisting CV disease contributed to the highest risk of CV mortality. Our study is limited by its retrospective nature.CONCLUSION: CV mortality represents a common event in patients with metastatic PCa treated with ADT. Preexisting CV disease represented the strongest risk factor.",
author = "Giorgio Gandaglia and Maxine Sun and Ioana Popa and Jonas Schiffmann and Vincent Trudeau and Shariat, {Shahrokh F} and Quoc-Dien Trinh and Markus Graefen and Hugues Widmer and Fred Saad and Alberto Briganti and Francesco Montorsi and Karakiewicz, {Pierre I}",
note = "Gro{\ss}e Abk{\"u}rzung fehlt, Journal ist gelistet",
year = "2015",
month = jun,
day = "1",
doi = "10.1016/j.clgc.2014.12.003",
language = "English",
volume = "13",
pages = "e123--130",
journal = "CLIN GENITOURIN CANC",
issn = "1558-7673",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study

AU - Gandaglia, Giorgio

AU - Sun, Maxine

AU - Popa, Ioana

AU - Schiffmann, Jonas

AU - Trudeau, Vincent

AU - Shariat, Shahrokh F

AU - Trinh, Quoc-Dien

AU - Graefen, Markus

AU - Widmer, Hugues

AU - Saad, Fred

AU - Briganti, Alberto

AU - Montorsi, Francesco

AU - Karakiewicz, Pierre I

N1 - Große Abkürzung fehlt, Journal ist gelistet

PY - 2015/6/1

Y1 - 2015/6/1

N2 - INTRODUCTION: The aim of our study was to reexamine the prevalence of baseline cardiovascular (CV) morbidity and the rates of CV mortality in a contemporary cohort of patients with prostate cancer (PCa) exposed to androgen deprivation therapy (ADT).MATERIALS AND METHODS: Records of patients aged 65 years and older with metastatic PCa who received ADT were abstracted from the Surveillance, Epidemiology, and End Results-Medicare database between 1991 and 2009. The primary end points comprised 5-year CV mortality rates. Survival rates were stratified according to age and Charlson comorbidity index (CCI). Competing-risks Poisson regression methodologies were performed.RESULTS: Overall, 9596 patients with metastatic PCa treated with ADT were identified. At baseline, 3049 patients (31.8%) had preexisting CV disease. The 5-year CV mortality rates were 9.8% and 14.8% in the overall population and in patients with preexisting CV disease, respectively. The 5-year CV mortality rates increased with advanced age and higher CCI score. In multivariate competing-risks regression analyses, age, year of diagnosis, CV comorbidities, CCI, and marital status represented independent predictors of CV mortality, after accounting for the risk of dying from other causes (all P ≤ .04). Of those, preexisting CV disease contributed to the highest risk of CV mortality. Our study is limited by its retrospective nature.CONCLUSION: CV mortality represents a common event in patients with metastatic PCa treated with ADT. Preexisting CV disease represented the strongest risk factor.

AB - INTRODUCTION: The aim of our study was to reexamine the prevalence of baseline cardiovascular (CV) morbidity and the rates of CV mortality in a contemporary cohort of patients with prostate cancer (PCa) exposed to androgen deprivation therapy (ADT).MATERIALS AND METHODS: Records of patients aged 65 years and older with metastatic PCa who received ADT were abstracted from the Surveillance, Epidemiology, and End Results-Medicare database between 1991 and 2009. The primary end points comprised 5-year CV mortality rates. Survival rates were stratified according to age and Charlson comorbidity index (CCI). Competing-risks Poisson regression methodologies were performed.RESULTS: Overall, 9596 patients with metastatic PCa treated with ADT were identified. At baseline, 3049 patients (31.8%) had preexisting CV disease. The 5-year CV mortality rates were 9.8% and 14.8% in the overall population and in patients with preexisting CV disease, respectively. The 5-year CV mortality rates increased with advanced age and higher CCI score. In multivariate competing-risks regression analyses, age, year of diagnosis, CV comorbidities, CCI, and marital status represented independent predictors of CV mortality, after accounting for the risk of dying from other causes (all P ≤ .04). Of those, preexisting CV disease contributed to the highest risk of CV mortality. Our study is limited by its retrospective nature.CONCLUSION: CV mortality represents a common event in patients with metastatic PCa treated with ADT. Preexisting CV disease represented the strongest risk factor.

U2 - 10.1016/j.clgc.2014.12.003

DO - 10.1016/j.clgc.2014.12.003

M3 - SCORING: Journal article

C2 - 25547676

VL - 13

SP - e123-130

JO - CLIN GENITOURIN CANC

JF - CLIN GENITOURIN CANC

SN - 1558-7673

IS - 3

ER -